|
1) Bruce WR, van der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature. 1963; 199: 79-80
|
|
|
|
2) Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukemia-initiating cells. Nature. 2008; 453: 1072-8
|
|
|
|
|
|
3) Cozzio A, Passegué E, Ayton PM, et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Gene Dev. 2003; 17: 3029-35
|
|
|
|
|
|
4) Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunol. 2004; 5: 738-43
|
|
|
|
|
|
5) Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 1997; 3: 730-7
|
|
|
|
|
|
6) Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100: 3983-8
|
|
|
|
|
|
7) Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63 5821-8
|
|
|
|
|
|
8) Richardson GD, Robson CN, Lang SH, et al. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 2004; 117: 3539-45
|
|
|
|
|
|
9) Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A. 2005; 102: 6942-7
|
|
|
|
|
|
10) Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445: 111-5
|
|
|
|
|
|
11) Prince ME, Sivanandan R, Kaczowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007; 104: 973-8
|
|
|
|
|
|
12) Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67: 3, 1030-7
|
|
|
|
|
|
13) Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem cell research. Nat Rev Cancer. 2005; 5: 311-21
|
|
|
|
|
|
14) Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003; 423: 255-60
|
|
|
|
|
|
15) Iwama A, Oguro H, Negishi M, et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity. 2004; 21: 843-51
|
|
|
|
|
|
16) Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005; 434: 843-50
|
|
|
|
|
|
17) Suzuki T, Chiba S. Notch signaling in hematopoietic stem cells. Int J Hematol. 2005; 82: 285-94
|
|
|
|
|
18) Zhang J, Grindley JC, Yin T, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature. 2006; 441: 518-22
|
|
|
|
|
|
19) Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006; 12: 1167-74
|
|
|
|
|
|
20) Krause DS, Lazarides K, von Andrian UH, et al. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006; 12: 1175-80
|
|
|
|
|
|
21) Holtz M, Forman SJ, Bhatia R. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res. 2007; 67: 1113-20
|
|
|
|
|
|
22) Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007; 109: 58-60
|
|
|
|
|
|
23) Cortes J, OʼBrien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004; 104: 2204-5
|
|
|
|
|
|
24) Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990; 247: 824-30
|
|
|
|
|
|
25) Lallemand-Breitenbach V, Zhu J, Puvion F, et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med. 2001; 193: 1361-71
|
|
|
|
|
|
26) Tatham MH, Geoffroy MC, Shen L, et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol. 2008; 10: 538-46
|
|
|
|
|
|
27) Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al. Arsenic degrades PML or PML-RAR alpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008; 10: 547-55
|
|
|
|
|